The US FDA is preparing to launch its website to publish the names of drug companies suspected of using risk evaluation and mitigation strategies (REMS) to stonewall generic sponsor access to samples, in a move Commissioner Scott Gottlieb insists is not meant to publicly shame the brand firms.
The website, which could be launched as early as May 17, will specifically contain the amount of "inquiries" there are...




